StageDebt - II | Alive
Last Raised$4.18M | 6 yrs ago
About LoneStar Heart
LoneStar Heart is a biomedical company developing new therapies to preserve and restore adequate heart function in patients with Advanced Heart Failure (HF). Based on its integrated cardiomechanical and biomolecular technologies, the company is developing a broad portfolio of products to restore the failing heart's structure and function in collaboration with the University of Texas Southwestern Medical Center, Texas Heart Institute, and a global network of leading clinicians. These products include Algisyl-LVR, small molecule cardiac stem-cell modulators, and cellular and genetic therapies delivered as stand-alone treatments, or in combination with the company's biopolymer hydrogel matrix system.
Missing: LoneStar Heart's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: LoneStar Heart's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing LoneStar Heart
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
LoneStar Heart is included in 2 Expert Collections, including Regenerative Medicine.
Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).
Startups developing new or improved materials (chemicals, alloys, etc.) that provide physical or functional advantages to basic materials.
Latest LoneStar Heart News
Oct 19, 2020
Disclosures: Solomon reports receiving grants from Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol-Myers Squibb, Celladon, Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, LoneStar Heart, Mesoblast, MyoKardia, Neurotronik, NIH/National Heart, Lung and Blood Institute, Novartis, Respicardia, Sanofi Pasteur, Theracos, and personal fees from Akros, Alnylam, Amgen, AoBiome, Arena, AstraZeneca, Bayer, Bristol-Myers Squibb, Cardiac Dimensions, Cardior, Cardurion, CellProThera, Corvia, Cytokinetics, Daiichi-Sankyo, Dinaqor, Gilead, GlaxoSmithKline, Ironwood, Janssen, Merck, Moderna, Myokardia, Novartis, Quantum Genetics, Roche, Sanofi-Pasteur, Takeda, Theracos, Tenaya and Tremeau outside the submitted work. Please see the study for all other authors’ relevant financial disclosures. Katz reports no relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact email@example.com . Back to Healio Approximately one-fifth of young adults hospitalized with COVID-19 required intensive care, according to research published in JAMA Internal Medicine. “We think the vast majority of people in this age range have self-limited disease and don't require hospitalization,” Scott Solomon, MD, director of noninvasive cardiology in the Division of Cardiovascular Medicine at the Brigham and Women’s Hospital, said in a press release. “But if you do, the risks are really substantial.” Reference: Cunningham JW, et al. JAMA Intern Med. 2020;doi:10.1001/jamainternmed.2020.531. Solomon and colleagues evaluated data from the Premier Healthcare Database, which includes 1,030 U.S. hospitals and health care systems, on adults aged 18 to 34 years with COVID-19 who were discharged from the hospital between April 1 and June 30. They identified 3,222 young adults with COVID-19 who were hospitalized at 419 U.S. hospitals. Among them, 36.8% were obese, 24.5% were morbidly obese, 18.2% had diabetes and 16.1% had hypertension. During their hospitalization, which was a median of 4 days, 21% of patients required intensive care, 10% required mechanical ventilation and 2.7% died. Solomon and colleagues identified a greater risk for death or mechanical ventilation among patients with morbid obesity (adjusted OR = 2.30; 95% CI, 1.77-2.98) and hypertension (adjusted OR = 2.36; 95% CI, 1.79-3.12) compared with those without such conditions. They also found that male patients had a greater risk for death or mechanical ventilation compared with female patients (adjusted OR = 1.53; 95% CI, 1.20-1.95). According to researchers, patients with multiple risk factors had similar COVID-19-related risks to adults aged 35 to 64 years with COVID-19 who did not have these conditions. Researchers noted that although the observed mortality rate of 2.7% was lower than the rate reported in older adults with COVID-19, this rate was higher than the mortality rate for other conditions requiring hospitalization in young adults. For instance, they found the observed mortality rate among young adults hospitalized for COVID-19 was double the rate associated with acute MI among adults the same age. In an editor’s note published alongside the study, Mitchell H. Katz, MD, president and CEO of NYC Health + Hospitals, said the findings provide more evidence that, unfortunately, “COVID-19 does not spare young people .” He added that the study confirms the novel coronavirus “is a life-threatening disease in people of all ages and that social distancing, facial coverings and other approaches to prevent transmission are as important in young adults as in older persons.” References:
LoneStar Heart Frequently Asked Questions (FAQ)
Where is LoneStar Heart's headquarters?
LoneStar Heart's headquarters is located at 15420 Laguna Canyon Road, Irvine.
What is LoneStar Heart's latest funding round?
LoneStar Heart's latest funding round is Debt - II.
How much did LoneStar Heart raise?
LoneStar Heart raised a total of $42.58M.
Who are the investors of LoneStar Heart?
Investors of LoneStar Heart include Themes Investment Partners.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.